[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100639834":3},{"organization":4,"outcomesModule":7,"designInfo":25,"detailedDescription":24,"studyPopulation":24,"armGroups":34,"interventions":46,"overallOfficials":24,"centralContacts":56,"locations":65,"responsibleParty":97,"collaborators":100,"id":102,"slug":24,"hasResults":103,"nctId":104,"briefTitle":105,"officialTitle":106,"acronym":24,"eligibilityCriteria":107,"healthyVolunteers":103,"sex":108,"minAge":109,"maxAge":24,"enrollmentInfo":110,"targetDuration":24,"studyType":113,"phases":114,"briefSummary":116,"conditions":117,"keywords":119,"overallStatus":68,"whyStopped":24,"lastUpdateSubmitDate":123,"lastUpdatePostDateStruct":124,"startDateStruct":127,"completionDateStruct":129,"leadSponsor":131,"locationsCount":132},{"fullName":5,"class":6},"Tartu University Hospital","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":24},[9],{"measure":10,"description":11,"timeFrame":12},"Occurence of symptomatic hypoparathyroidism","Occurrence of symptomatic hypoparathyroidism within 14 days postoperatively","2 weeks",[14,17,21],{"measure":15,"description":16,"timeFrame":12},"Serum calcium levels at 2 week follow-up","Comparison of serum calcium levels at the 2-week follow-up between lower- and higher-dose calcium replacement groups.",{"measure":18,"description":19,"timeFrame":20},"Duration and permanence of hypoparathyroidism","Assessment of whether postoperative hypoparathyroidism resolves (transient) or persists (permanent) during follow-up.","Up to 12 months postoperatively",{"measure":22,"description":23,"timeFrame":12},"Serum parathyroid hormone (PTH) levels at 2 week follow-up","Comparison of serum parathyroid hormone (PTH) levels at the 2-week follow-up between lower- and higher-dose calcium replacement groups.",null,{"allocation":26,"interventionModel":27,"interventionModelDescription":28,"primaryPurpose":29,"observationalModel":24,"timePerspective":24,"maskingInfo":30},"RANDOMIZED","PARALLEL","This study evaluates different dosing regimens of a widely used calcium preparation; as the drug is already approved and commonly used, a clinical trial phase is not applicable","TREATMENT",{"masking":31,"maskingDescription":24,"whoMasked":32},"SINGLE",[33],"PARTICIPANT",[35,41],{"label":36,"type":37,"description":38,"interventionNames":39},"Lower dose calcium replacement","ACTIVE_COMPARATOR","calcium carbonate 1250 mg x 2",[40],"Drug: Calcium carbonate 1250 mg (500 mg elemental calcium) twice a day",{"label":42,"type":37,"description":43,"interventionNames":44},"Higher dose calcium replacement","calcium carbonate 1250 mg x 4",[45],"Drug: Calcium carbonate 1250 mg (500 mg elemental calcium) 4 times a day",[47,52],{"type":48,"name":49,"description":50,"armGroupLabels":51,"otherNames":24},"DRUG","Calcium carbonate 1250 mg (500 mg elemental calcium) twice a day","One study group takes calcium carbonate 1250 mg (500 mg elemental calcium) twice a day (at lunchtime and in the evening)",[36],{"type":48,"name":53,"description":54,"armGroupLabels":55,"otherNames":24},"Calcium carbonate 1250 mg (500 mg elemental calcium) 4 times a day","The second study group takes 1250 mg of calcium carbonate (500 mg of elemental calcium) four times a day (starting at noon, at approximately 4-hour intervals: at noon, in the early afternoon, in the evening, and before bedtime). This dosage regimen is prescribed because 500 mg of calcium can be absorbed at a time.",[42],[57,62],{"name":58,"role":59,"phone":60,"phoneExt":24,"email":61},"Hanna Hollman","CONTACT","+37259037517","hanna.hollman@ut.ee",{"name":63,"role":59,"phone":64,"phoneExt":24,"email":24},"Ceith Nikkolo","+372 53318092",[66,85],{"facility":67,"status":68,"city":69,"state":70,"zip":71,"country":72,"countryCode":73,"cosmosGeoPoint":74,"geoPoint":79,"contacts":80},"East Tallinn Central Hospital","RECRUITING","Tallinn","Other","11914","Estonia","EE",{"type":75,"coordinates":76},"Point",[77,78],24.75353,59.43696,{"lat":78,"lon":77},[81],{"name":82,"role":59,"phone":83,"phoneExt":24,"email":84},"Hanna Hollman, MD","+ 372 59037517","hanna.hollman@itk.ee",{"facility":5,"status":68,"city":86,"state":24,"zip":24,"country":72,"countryCode":73,"cosmosGeoPoint":87,"geoPoint":91,"contacts":92},"Tartu",{"type":75,"coordinates":88},[89,90],26.72509,58.38062,{"lat":90,"lon":89},[93],{"name":94,"role":59,"phone":95,"phoneExt":24,"email":96},"Ceith Nikkolo, PhD","+372 53319082","ceith.nikkolo@kliinikum.ee",{"type":98,"investigatorFullName":63,"investigatorTitle":99,"investigatorAffiliation":5,"oldNameTitle":24,"oldOrganization":24},"PRINCIPAL_INVESTIGATOR","general surgeon, PhD",[101],{"name":67,"class":6},"100639834",false,"NCT07577570","Calcium Replacement Therapy in Postoperative Hypoparathyroidism","A Pilot Study of Calcium Replacement Therapy in Postoperative Hypoparathyroidism","Inclusion Criteria:\n\n* patients over the age of 18 undergoing surgery involving both lobes of the thyroid gland (thyroidectomy, \"near-total\" thyroidectomy, subtotal thyroidectomy, and \"completed\" thyroidectomy)\n* Based on the first post-operative day analysis, PTH levels are below the normal range (in our hospitals 1.8-7.8 pmol\u002Fl), but not so low (below 1.06 pmol\u002FL) as to require calcium replacement therapy with calcitriol (rocaltrol)\n\nExclusion Criteria:\n\n* previously diagnosed osteoporosis; the patient is already taking calcium and vitamin D supplements prior to thyroid surgery\n* renal insufficiency (eGFR \\\u003C 30)\n* patients with concomitant hyperparathyroidism undergoing simultaneous thyroidectomy and parathyroidectomy for a parathyroid adenoma","ALL","18 Years",{"count":111,"type":112},50,"ESTIMATED","INTERVENTIONAL",[115],"NA","The goal of this clinical trial is to evaluate whether a lower-dose calcium replacement therapy is non-inferior to a higher-dose regimen in preventing symptomatic hypoparathyroidism in patients following thyroidectomy. The hypothesis is:\n\n• lower-dose calcium replacement therapy is non-inferior to higher-dose therapy in preventing symptomatic hypoparathyroidism during the first two postoperative weeks\n\nResearchers will compare patients receiving a lower-dose calcium replacement regimen with those receiving a higher-dose regimen to assess whether the lower dose is not associated with a higher incidence of symptomatic hypoparathyroidism.\n\nPatients who develop post-thyroidectomy hypoparathyroidism are divided into groups for calcium replacement therapy. If they are asymptomatic, they will be scheduled for a follow-up visit at two weeks after surgery. During the follow-up visit, calcium metabolism will be evaluated, and treatment adjusted if necessary.",[118],"Post-Thyroidectomy Hypoparathyroidism Treatment",[120,121,122],"thyroidectomy","calcium replacement therapy","postoperative hypoparathyroidism","2026-05-05",{"date":125,"type":126},"2026-05-11","ACTUAL",{"date":128,"type":126},"2025-11-18",{"date":130,"type":112},"2028-12",{"name":5,"class":6},2]